Asset-light pharma services are entering a new era as pharmaceutical companies grapple with increasingly complex regulatory, commercial and technological challenges. Although growth in pharma commercialisation has slowed sharply from pre-pandemic levels, panellists at the Asset-light pharma service presentation at Investors in Healthcare’s Private Capital Conference in June argued that improving biotech funding, a growing pipeline of drug launches, rising pharmaceutical spending and continued outsourcing are creating renewed opportunities for specialist service providers.
Private equity investors continue to be attracted to the sector, but the characteristics of the most appealing businesses are evolving. Rather than simply outsourcing routine activities, pharma companies are seeking partners that combine deep therapeutic and regulatory expertise with proprietary data, AI-enabled capabilities and technologies embedded within commercial workflows.
Speakers identified several structural shifts reshaping the market, from changing launch strategies and earlier evidence generation to AI adoption and the consumerisation of healthcare.
More sophisticated launch strategies
Commercialisation planning is becoming more strategic. While the US remains the priority launch market for most pharmaceutical companies, evolving pricing policies and reimbursement dynamics are prompting companies to reassess how they sequence launches across other regions.
The prospect of international reference pricing and most-favoured nation policies in the US has increased scrutiny of launch sequencing, particularly in lower-priced European markets where reimbursement decisions could have wider implications. At the same time, emerging commercial opportunities in regions such as the Middle East and Latin America are moving higher up companies’ launch priorities.
Rather than following a standard geographical playbook, panellists argued that launch sequencing is becoming evidence-led, with companies assessing each market individually according to unmet clinical need, commercial potential and reimbursement dynamics.
Success depends on demonstrating clinical, economic and societal value well before launch. Alongside clinical efficacy, companies must build compelling evidence around health economics, patient outcomes and broader societal impact, tailoring those messages to individual healthcare systems and stakeholder groups.
Speakers noted that many disappointing launches can be traced back to insufficient market insight rather than shortcomings in the underlying product, reinforcing the importance of specialist commercial advisory services.
Evidence moves upstream
The panel also highlighted how evidence generation is moving much earlier in the product development cycle.
Historically, real-world evidence was often viewed primarily as a tool to support reimbursement and regulatory submissions after clinical development. However, companies are more-widely incorporating evidence strategies much earlier, with Phase II already considered late for addressing some commercial questions.
Earlier evidence generation enables pharmaceutical companies and investors to evaluate issues such as physician adoption, treatment differentiation and commercial positioning long before launch. This helps identify potential weaknesses while there is still time to address them, reducing both clinical and commercial risk.
Real-world evidence has also become a more sophisticated investment tool, allowing investors to assess commercial differentiation and likely physician adoption much earlier in the development process. Beyond estimating addressable markets, investors are using increasingly rich datasets to understand competitive positioning, prescribing behaviour and likely market adoption much earlier in the development process.
As innovation becomes more global, evidence strategies are also becoming more complex. The panel pointed to the growing volume of innovation emerging from China and wider Asia, expanding the need for service providers capable of navigating different regulatory systems and supporting cross-border development and commercialisation.
AI raises the value of expertise
Artificial intelligence underpinned much of the discussion, although speakers consistently argued that its greatest impact lies not in replacing expertise but in amplifying its value.
Many pharmaceutical companies have already embraced AI in drug discovery and development. Commercial functions are following, although adoption varies considerably between regions because of differing regulatory and privacy requirements.
Across commercialisation, AI is improving operational efficiency by automating repetitive activities, synthesising information and accelerating content generation. However, speakers suggested that the greatest long-term opportunity lies in using AI to improve decision-making rather than simply reduce costs.
Examples include analysing physician behaviour to recommend next-best actions, supporting evidence generation, automating elements of health technology assessment and extracting insights from ever-more complex healthcare datasets.
At the same time, AI is reshaping competitive dynamics within the services industry itself.
Routine activities are becoming more automated, placing pricing pressure on more standardised services. By contrast, strategic advisory work involving regulatory judgement, market access strategy and scientific expertise is becoming more valuable.
One panellist observed that while AI can dramatically improve the efficiency of regulated processes such as compliance reviews, ultimate accountability still rests with experienced professionals. Human judgement therefore remains essential, even as AI transforms underlying workflows.
The discussion also highlighted a broader transition from traditional time-and-materials consulting models towards product-based businesses. Developing proprietary AI tools offers opportunities for recurring revenues and greater scalability, but also requires capabilities more commonly associated with software companies, including product development, maintenance and continuous improvement.
Patients become consumers
Another major theme was the growing consumerisation of healthcare.
Driven by the rapid adoption of GLP-1 therapies, telehealth, digital pharmacies and online health information, patients are becoming far more active participants in their own care.
Rather than focusing solely on raising awareness, pharmaceutical companies are seeking to engage patients throughout the care pathway – from education and telehealth to prescribing, treatment adherence and outcomes monitoring.
This evolution creates significant opportunities for companies specialising in patient engagement, digital communications and connected healthcare services.
At the same time, the explosion of digital channels makes trust an enormously valuable asset.
As healthcare professionals and patients receive information from an expanding range of sources, including social media and AI-generated content, maintaining scientific credibility and trusted communications becomes a key competitive differentiator for specialist agencies.
While direct-to-consumer engagement remains more advanced in the US than Europe because of differing regulatory frameworks, speakers argued that the broader shift towards patient-centred healthcare is likely to accelerate globally.
Defensible platforms attract investors
The discussion concluded by examining what investors are searching for in emerging asset-light pharma businesses.
While AI-enabled point solutions continue to attract attention, enthusiasm has become more selective. Investors are looking beyond rapid early growth towards businesses capable of building sustainable competitive advantages.
Two characteristics stood out.
The first is proprietary data and learning capabilities that improve over time, creating solutions that become progressively stronger with each customer interaction and increasingly difficult to replicate.
The second is deep integration within pharmaceutical workflows. Solutions embedded in day-to-day operations benefit from higher switching costs and stronger customer relationships, making them more attractive platform investments than standalone applications.
Taken together, these themes point to an important evolution within asset-light pharma services.
Rather than competing primarily on scale or execution capacity, asset-light pharma service providers are differentiating themselves through specialist expertise, proprietary technology, trusted relationships and embedded workflows. As pharmaceutical companies navigate more complex launch strategies, earlier evidence requirements, AI adoption and rising consumer-driven healthcare, demand for those capabilities looks set to grow.
For investors, the opportunity lies not simply in identifying fast-growing service providers, but in finding businesses that combine domain expertise, differentiated technology and durable competitive advantages.
